vs
Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $92.9M, roughly 1.3× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 5.0%, a 20.0% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 18.2%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $9.1M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 18.9%).
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
HIPO vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $120.4M | $92.9M |
| Net Profit | $6.0M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 5.6% | 24.1% |
| Net Margin | 5.0% | 25.0% |
| Revenue YoY | 18.2% | 23.3% |
| Net Profit YoY | -86.4% | 17.3% |
| EPS (diluted) | $0.31 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.4M | $92.9M | ||
| Q3 25 | $120.6M | $67.5M | ||
| Q2 25 | $117.3M | $63.2M | ||
| Q1 25 | $110.3M | $52.6M | ||
| Q4 24 | $101.9M | $75.4M | ||
| Q3 24 | $95.5M | $57.9M | ||
| Q2 24 | $89.6M | $52.7M | ||
| Q1 24 | $85.1M | $51.3M |
| Q4 25 | $6.0M | $23.2M | ||
| Q3 25 | $98.1M | $5.1M | ||
| Q2 25 | $1.3M | $-553.0K | ||
| Q1 25 | $-47.7M | $-11.2M | ||
| Q4 24 | $44.2M | $19.8M | ||
| Q3 24 | $-8.5M | $-901.0K | ||
| Q2 24 | $-40.5M | $-4.7M | ||
| Q1 24 | $-35.7M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 5.6% | 24.1% | ||
| Q3 25 | 81.3% | 5.1% | ||
| Q2 25 | 3.4% | -3.2% | ||
| Q1 25 | -41.3% | -24.3% | ||
| Q4 24 | 46.3% | 24.5% | ||
| Q3 24 | -5.4% | -4.3% | ||
| Q2 24 | -40.7% | -11.5% | ||
| Q1 24 | -38.7% | -10.7% |
| Q4 25 | 5.0% | 25.0% | ||
| Q3 25 | 81.3% | 7.5% | ||
| Q2 25 | 1.1% | -0.9% | ||
| Q1 25 | -43.2% | -21.4% | ||
| Q4 24 | 43.4% | 26.3% | ||
| Q3 24 | -8.9% | -1.6% | ||
| Q2 24 | -45.2% | -8.9% | ||
| Q1 24 | -42.0% | -7.5% |
| Q4 25 | $0.31 | $0.46 | ||
| Q3 25 | $3.77 | $0.10 | ||
| Q2 25 | $0.05 | $-0.01 | ||
| Q1 25 | $-1.91 | $-0.23 | ||
| Q4 24 | $1.81 | $0.40 | ||
| Q3 24 | $-0.34 | $-0.02 | ||
| Q2 24 | $-1.64 | $-0.10 | ||
| Q1 24 | $-1.47 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.3M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $436.1M | $354.6M |
| Total Assets | $1.9B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.3M | $137.5M | ||
| Q3 25 | $247.7M | $135.4M | ||
| Q2 25 | $198.9M | $116.9M | ||
| Q1 25 | $140.9M | $112.9M | ||
| Q4 24 | $197.6M | $116.2M | ||
| Q3 24 | $191.2M | $101.7M | ||
| Q2 24 | $175.9M | $102.5M | ||
| Q1 24 | $223.4M | $110.6M |
| Q4 25 | $436.1M | $354.6M | ||
| Q3 25 | $421.5M | $321.9M | ||
| Q2 25 | $332.5M | $306.8M | ||
| Q1 25 | $322.8M | $295.5M | ||
| Q4 24 | $362.1M | $292.0M | ||
| Q3 24 | $326.4M | $257.5M | ||
| Q2 24 | $322.6M | $243.0M | ||
| Q1 24 | $351.2M | $233.9M |
| Q4 25 | $1.9B | $488.0M | ||
| Q3 25 | $1.9B | $453.3M | ||
| Q2 25 | $1.7B | $435.6M | ||
| Q1 25 | $1.5B | $424.6M | ||
| Q4 24 | $1.5B | $432.7M | ||
| Q3 24 | $1.5B | $390.4M | ||
| Q2 24 | $1.5B | $376.8M | ||
| Q1 24 | $1.5B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $15.0M |
| Free Cash FlowOCF − Capex | $9.1M | $12.8M |
| FCF MarginFCF / Revenue | 7.6% | 13.8% |
| Capex IntensityCapex / Revenue | 0.1% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.53× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $14.8M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $15.0M | ||
| Q3 25 | $16.9M | $22.1M | ||
| Q2 25 | $24.7M | $8.2M | ||
| Q1 25 | $-35.6M | $6.6M | ||
| Q4 24 | $47.5M | $22.2M | ||
| Q3 24 | $46.8M | $10.2M | ||
| Q2 24 | $-10.6M | $18.5M | ||
| Q1 24 | $17.7M | $7.2M |
| Q4 25 | $9.1M | $12.8M | ||
| Q3 25 | $16.8M | $19.5M | ||
| Q2 25 | $24.6M | $81.0K | ||
| Q1 25 | $-35.7M | $-7.6M | ||
| Q4 24 | $47.2M | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | $-10.7M | $1.8M | ||
| Q1 24 | $17.6M | $-6.8M |
| Q4 25 | 7.6% | 13.8% | ||
| Q3 25 | 13.9% | 28.8% | ||
| Q2 25 | 21.0% | 0.1% | ||
| Q1 25 | -32.4% | -14.5% | ||
| Q4 24 | 46.3% | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | -11.9% | 3.4% | ||
| Q1 24 | 20.7% | -13.3% |
| Q4 25 | 0.1% | 2.4% | ||
| Q3 25 | 0.1% | 3.9% | ||
| Q2 25 | 0.1% | 12.9% | ||
| Q1 25 | 0.1% | 27.0% | ||
| Q4 24 | 0.3% | 18.3% | ||
| Q3 24 | 0.0% | 33.5% | ||
| Q2 24 | 0.1% | 31.8% | ||
| Q1 24 | 0.1% | 27.3% |
| Q4 25 | 1.53× | 0.65× | ||
| Q3 25 | 0.17× | 4.35× | ||
| Q2 25 | 19.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.07× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HIPO
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
